24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2022
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2022 VC Survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Weight Loss
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
18:32
Why Monday.com’s impressive revenue jump wasn’t enough for Wall Street
14:52
"We have a bitcoin president!" The real winner in the US election
12:59
Pandemic high to deep decline: How LivePerson’s valuation dropped from $4.7B to $60M
12:00
Viola Ventures' next fund to be led by Zvika Orron and Omry Ben David, together with founder Shlomo Dovrat
More stories
Buzz
Most popular
Daily
Weekly
1
$100M in savings not enough to justify Intel’s coffee cut
2
Cyber startup Upwind raising $100 million at $850-900M valuation
3
Viola Ventures' next fund to be led by Zvika Orron and Omry Ben David, together with founder Shlomo Dovrat
4
CrowdStrike acquires Adaptive Shield in $300M deal to boost SaaS security
5
Why Monday.com’s impressive revenue jump wasn’t enough for Wall Street
More news
Weight Loss
4 stories about Weight Loss
Epitomee surges 200% in two days on FDA approval for weight loss pill
16.09.24
|
Adiel Eithan Mustaki
Investors are hopeful, but the company must now face an uphill battle in a crowded market.
Weight loss pill maker Epitomee’s stock sinks 70% after Nestlé cancels agreement
04.12.23
|
Adiel Eithan Mustaki
The Swiss conglomerate notified Epitomee that it has decided not to market its product as the clinical trial results measuring the disparity in the weight loss rate between patients who took the pill and the control group did not reach the previously agreed upon success level
Weight loss pill success sparks stock surge at Epitomee Medical
04.09.23
|
Adiel Eithan Mustaki
The company, which has not yet published the full results of its study, plans to seek FDA approval via the 510(k) pathway
Teva Israel to Stop Distribution of Weight Loss Drug Amid Cancer Concerns
16.02.20
|
Lilach Baumer
On Thursday, the manufacturer of Belviq weight loss drug, Eisai, announced it was withdrawing the drug from the U.S. market after a five-year trial found it increased risk of cancer by 0.6%
Please ensure Javascript is enabled for purposes of
website accessibility